<p>INTRODUCTION</p><p>SECTION I: GENERAL PRINCIPLES</p><p>SECTION II: MOLECULAR TARGETING OF CANCER CELLS</p><p>1. DNA DAMAGING DRUGS<br>1.1. ALKYLATING AGENTS<br>1.2. ANTIBIOTICS<br>1.3. TOPOISOMERASE INHIBITORS<br>1.4. ANTI-METABOLITES</p><p>2. DRUGS THAT SUPPRESS PROLIFERATION<br>2.1. ANTI-MITOTIC AGENTS<br>2.2. DIFFERENTIATING AGENTS<br>2.3. INDUCERS OF APOPTOSIS</p><p>3. MOLECULAR INHIBITORS OF GROWTH SIGNALS<br>3.1. SMALL MOLECULE KINASE INHIBITORS<br>3.2. INHIBITORS OF ONCOGENE FUNCTIONS<br>3.3. ANTIBODIES</p><p>4. ANTI-METASTASIS THERAPY<br>4.1. INTEGRIN INHIBITORS<br>4.2. CD44 INHIBITORS<br>4.3. MMP INHIBITORS<br>4.4. CHEMOKINE RECEPTOR INHIBITORS<br>4.5. TGF- IHIBITORS<br>4.6. BONE TARGETING AGENTS<br>4.7. OTHERS</p><p>5. INDUCTION OF SENESCENCE<br>5.1. TELOMERASE INHIBITORS</p><p>6. COMBINATION CHEMOTHERAPY<br>6.1. TREATMENT OF HEMATOLOGIC MALIGNANCIES<br>6.2. TREATMENT OF SOLID TUMORS</p><p>SECTION III: EMERGING AND ALTERNATIVE TREATMENT MODALITIES</p><p>7. GENE THERAPY<br>7.1. GENE SILENCING<br>7.2. SUICIDE GENES<br>7.3. ONCOLYTIC VIRUSES<br>7.4. GENE DELIVERY<br>7.5. OTHER STRATEGIES</p><p>8. DRUGS WITH DIVERSE MODES OF ACTION</p><p>SECTION IV: MOLECULAR TARGETING OF TUMOR-HOST INTERACTIONS</p><p>9. HORMONE THERAPY<br>9.1. ANTI-ESTROGENS<br>9.2. ANTI-ANDROGENS<br>9.3. CORTICOSTEROIDS</p><p>10. IMMUNOTHERAPY<br>10.1. IMMUNOTOXINS<br>10.2. ENGINEERED ANTIBODIES<br>10.3. ANTIGEN BASED IMMUNOTHERAPIES<br>10.4. CYTOKINE BASED IMMUNOTHERAPIES<br>10.5. IMMUNE RESPONSE MODIFIERS<br>10.6. AUTOLOGOUS THERAPIES<br>10.7. OTHER REGIMENS</p><p>11. ANTI-ANGIOGENESIS<br>11.1. VEGF ANTAGONISTS<br>11.2. FGF-2 ANTAGONISTS<br>11.3. THALIDOMIDE RELATED DRUGS<br>11.4. INTEGRIN BLOCKERS<br>11.5. ENDOSTATIN AND ANGIOSTATIN<br>11.6. OTHERS</p><p>SECTION V: ANTI-CANCER DRUG PHARMACOKINETICS</p><p>12. DRUG DELIVERY AND DRUG TRANSPORT<br>12.1. TARGETING WITH DRUG CONJUGATES <br>12.2.</p> RADIO-TARGETING<br>12.3. NANO-PARTICLES<br>12.4. SOLUBILIZERS<br>12.5. VARIOUS<p></p><p>13. DRUG METABOLISM<br>13.1. CYP450<br>13.2. FLAVIN MONOOXYGENASES<br>13.3. GST<br>13.4. OTHERS</p><p>14. PRODRUG ACTIVATION<br>14.1. PHOTODYNAMIC THERAPY<br>14.2. RADIO-SENSITIZATION</p><p>15. DRUG RESISTANCE<br>15.1. INCREASED EFFLUX<br>15.2. DECREASED UPTAKE <br>15.3. ANTI-APOPTOSIS<br>15.4. MUTATIONS IN THE DRUG TARGET<br>15.5. ALTERED REPAIR OF DRUG INDUCED DAMAGE<br>15.6. OTHER MECHANISMS</p><p>SECTION VI: SUPPORTIVE THERAPY</p><p>16. PROTECTION FROM ADVERSE EFFECTS<br>16.1. ANTI-EMETICS <br>16.2. PROTECTION FROM ANEMIA<br>16.3. IMMUNE RECOVERY<br>16.4. CARDIOVASCULAR PROTECTION<br>16.5. ANTI-OXIDANTS<br>16.6. ANTI-CACHEXIA DRUGS<br>16.7. PROTECTION FROM HEPATOTOXICITY <br>16.8. PROTECTION FROM URINARY TOXICITY<br>16.9. PROTECTION OF THE GASTROINTESTINAL TRACT<br>16.10. TREATMENT OF DERMATOLOGIC REACTIONS TO CHEMOTHERAPY <br>16.11. ELECTROLYTE BALANCE<br>16.12. REPRODUCTIVE PROTECTION<br>16.13. OTHERS</p><p>17. PAIN MANAGEMENT<br>17.1. NON-STEROIDAL DRUGS<br>17.2. OPIOID DRUGS<br>17.3. OTHERS</p><p>18. PREVENTIVE TREATMENT<br>18.1. VACCINES<br>18.2. CHEMOPREVENTION</p>
